BRENTWOOD, Tenn. / Aug 28, 2024 / Business Wire / Ardent Health Partners, Inc. (NYSE: ARDT) (“Ardent Health” or the “Company”), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the Company will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference being held September 4-6, 2024, in New York, NY.
Ardent Health President and Chief Executive Officer Marty Bonick and Chief Financial Officer Alfred Lumsdaine will take part in a fireside chat at the conference beginning at 10:00 a.m. ET on Thursday, September 5, 2024. A live audio webcast of the presentation will be available at the Investor Relations section of the Company’s website, at https://ir.ardenthealth.com, and a replay will be available for 90 days using the same link.
In conjunction with the conference, the Ardent Health management team will be available to participate in one-on-one meetings with investors registered to attend the conference. Interested investors should contact their Morgan Stanley representative to schedule meetings.
About Ardent Health
Ardent Health (NYSE: ARDT) is a leading provider of healthcare in growing mid-sized urban communities across the U.S. With a focus on people and investments in innovative services and technologies, Ardent is passionate about making healthcare better and easier to access. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and more than 200 sites of care with over 1,700 affiliated providers across six states. For more information, please visit www.ardenthealth.com.
Last Trade: | US$16.27 |
Daily Volume: | 562,645 |
November 06, 2024 August 14, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB